HONZ(SZ:300086) Xin Lang Cai Jing·2025-10-10 01:51Group 1 - The core viewpoint of the news is that Kangzhi Pharmaceutical has seen a stock price increase of 5.24%, reaching 7.23 CNY per share, with a total market capitalization of 3.291 billion CNY [1] - Kangzhi Pharmaceutical, established on January 20, 1994, and listed on May 26, 2010, is a leading domestic children's health enterprise in China, focusing on the research, production, and sales of children's medicine and maternal and infant health products [1] - The company's main business revenue composition includes 76.16% from children's medicine, 20.89% from adult medicine, and 2.94% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Kangzhi Pharmaceutical, the Nuoan Multi-Strategy Mixed A Fund (320016) has recently entered the list, holding 1.9087 million shares, which accounts for 0.43% of the circulating shares [2] - The Nuoan Multi-Strategy Mixed A Fund has achieved a year-to-date return of 60.31%, ranking 752 out of 8166 in its category, and a one-year return of 89%, ranking 163 out of 8014 [2] - The fund manager, Kong Xianzheng, has a tenure of 4 years and 319 days, with a best fund return of 74.86% during his management period [3]